A Phase I clinical study evaluating single-ascending doses of NKTR-358 in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 09 May 2017
At a glance
- Drugs NKTR 358 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- 09 May 2017 According to a Nektar Therapeutics media release, company plan to report the results from this trial at a medical meeting in the second half of 2017.
- 30 Mar 2017 New trial record
- 27 Mar 2017 According to a Nektar Therapeutics media release, company today announced that it has begun dosing in this clinical study.